ArticleCardiovascular diabetology2026
Association of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose and its modified indices with cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a longitudinal analysis based on CHARLS.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo evaluate the incremental predictive value of modifying the C-reactive protein-triglyceride-glucose (CTI) index with obesity parameters for incident cardiovascular disease (CVD) across Cardiovascular-Kidney-Metabolic (CKM) syndrome stages.
methodsBased on the longitudinal CHARLS cohort, Cox proportional hazards was utilized. Predictive increments were assessed using time-dependent Nearest Neighbor Estimation (NNE) AUC with Bootstrap resampling, cNRI, and IDI. Pathophysiological mechanisms were explored via Weighted Quantile Sum (WQS) regression and causal mediation analyses.
resultsAfter adjusting for demographic and clinical confounders, CTI and its modified indices all maintained robust, independent associations with incident CVD. Specifically, except for CTI-BMI, the new index, which incorporates the obesity index, transforms the dose-response relationship from a complex, nonlinear pattern to a threshold linear association. While increments in overall discrimination (AUC) were marginal, both baseline and cumulative CTI-CVAI significantly improved risk reclassification(cNRI: 0.093-0.126, IDI: 0.024-0.026, P < 0.001). The CKM stratification reveals stage-dependent predictive effects, with amplified relative risks in CKM 0-2 stages and stronger incremental value for risk reclassification in the CKM 3 stage. WQS confirmed visceral adiposity as the dominant risk driver, and physical frailty was identified as a significant pathophysiological mediator of the observed associations.
conclusionsIncorporating obesity indicators, particularly CVAI, into the CTI framework significantly improves the reclassification of CVD risk in early to moderate CKM stages. However, the lack of significant discriminative (AUC) improvement necessitates a careful clinical trade-off between adopting complex composite metrics and maintaining screening feasibility.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.